LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Search

Simulations Plus Inc

Cerrado

SectorSanidad

12.23 1.07

Resumen

Variación precio

24h

Actual

Mínimo

11.51

Máximo

12.35

Métricas clave

By Trading Economics

Ingresos

1.4M

676K

Ventas

961K

18M

P/B

Media del Sector

48.528

108.767

Rentabilidad por dividendo

0.48

Margen de beneficios

3.67

Empleados

212

EBITDA

-3M

2.3M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+57.15% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.21%

Próximas Ganancias

2 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-138M

230M

Apertura anterior

11.16

Cierre anterior

12.23

Noticias sobre sentimiento de mercado

By Acuity

23%

77%

52 / 352 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 feb 2026, 23:53 UTC

Acciones populares

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 feb 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27 feb 2026, 17:55 UTC

Acciones populares

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27 feb 2026, 23:46 UTC

Adquisiciones, fusiones, absorciones

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 feb 2026, 23:33 UTC

Adquisiciones, fusiones, absorciones

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 feb 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

27 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

27 feb 2026, 21:30 UTC

Ganancias

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 feb 2026, 21:30 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 feb 2026, 21:20 UTC

Adquisiciones, fusiones, absorciones

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 feb 2026, 21:17 UTC

Ganancias

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb 2026, 21:10 UTC

Adquisiciones, fusiones, absorciones

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 feb 2026, 21:09 UTC

Adquisiciones, fusiones, absorciones

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 feb 2026, 21:00 UTC

Ganancias

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 feb 2026, 20:31 UTC

Adquisiciones, fusiones, absorciones

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 feb 2026, 20:24 UTC

Charlas de Mercado

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 feb 2026, 20:23 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 feb 2026, 20:12 UTC

Charlas de Mercado

Nike Seen With Further Challenges in China -- Market Talk

27 feb 2026, 19:44 UTC

Charlas de Mercado

Gold Caps Historic Month -- Market Talk

27 feb 2026, 19:39 UTC

Ganancias

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb 2026, 19:38 UTC

Ganancias

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27 feb 2026, 18:53 UTC

Adquisiciones, fusiones, absorciones

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27 feb 2026, 18:45 UTC

Ganancias

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27 feb 2026, 18:45 UTC

Charlas de Mercado

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27 feb 2026, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

27 feb 2026, 17:07 UTC

Ganancias

Pemex Cuts 4Q Loss As Operating Results Improve

27 feb 2026, 17:00 UTC

Charlas de Mercado

Corn Rides Oil Momentum Higher -- Market Talk

27 feb 2026, 16:31 UTC

Charlas de Mercado

Canadian Economy Shows Resilience -- Market Talk

27 feb 2026, 16:17 UTC

Charlas de Mercado

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27 feb 2026, 15:49 UTC

Ganancias

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

57.15% repunte

Estimación a 12 Meses

Media 19 USD  57.15%

Máximo 19 USD

Mínimo 19 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

52 / 352 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat